ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1101

Extracellular Vesicle-Mediated Delivery of EBV SMALL RNA (EBER1) Activates LUPUS Nephritis Related Antiviral Immunity in Tubular Epithelial CELLS VIA TLR3

R Baglio1, M Tsang-A-Sjoe2, M Eijndhoven1, K Jordanova3, N Groenewegen1, J van Weering4, S Verkuijlen1, Irene E.M. Bultink5, J Middeldorp6, J Roelofs7, Alexandre Voskuyl8 and M Pegtel1, 1pathology, VU University medical center, Amsterdam, Netherlands, 2Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, 3gynaecologic oncology, VU University medical center, Amsterdam, Netherlands, 4functional genomics, VU University medical center, Amsterdam, Netherlands, 5Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 6pathology, VU Uninersity medical center, Amsterdam, Netherlands, 7pathology, Amsterdam Medical Center, Amsterdam, Netherlands, 8Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: SLE and nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In lupus nephritis (LN), genetic and environmental factors drive the chronic activation of antiviral defenses leading to immune complex-mediated glomerular and tubular damage. Increasing evidence suggests the involvement of extracellular vesicles (EVs) in autoimmune disease. Currently a role for EVs in the pathogenesis of lupus nephritis has not been proposed. Objectives: To investigate the role of EVs in the pathogenesis of LN.

Methods: To determine the presence of EVs in kidneys, biopsies from LN patients and IgA- nephropathy and Focal Segmental Glomerulosclerosis control patients were used. Serum samples from SLE patients and from RA patients as controls were used to determine the presence of circulating EVs. Primary renal tubular epithelial cells (TEC) were cultured, and Kidney injury molecule-1 (KIM1) expression was assessed by FACS. Exosomes were analyzed by electron microscopy and western blot. mRNA analysis was performed by qPCR. TLR3 inhibition was performed with TLR3/dsRNA complex inhibitor and with hydroxychloroquine.

Results: We show that EVs deliver virus-derived small RNA and activate TEC via toll-like receptor 3 (TLR3). Highly specific stem-loop RT-PCRs revealed Epstein Barr Virus (EBV)-encoded small RNAs in LN biopsies while quantitative EBV-DNA PCR, sensitive to a single copy was negative. In situ hybridization failed to detect nuclear EBV-EBER1 (i.e. EBV-infected cells) in LN biopsies. However, we observed atypical EBER signal in the cytoplasm of TECs in LN but not in disease control biopsies, suggestive of uptake of extra-renal EBER. Consistent with this, we detected EBER1 in circulating EVs of SLE sera. The LN tissues express strongly elevated levels of TLR3, Interferon induced transmembrane-1 and -3, and TNFα. Primary TEC cultured in vitro endocytose EBER1-EVs secreted by EBV-infected B cells via phosphatidylserine receptors such as KIM-1. Importantly, EV-EBER1 uptake by TEC triggers antiviral immunity and pro-inflammatory cytokine secretion in a Toll-like receptor 3 (TLR3)-dependent manner. Treatment with hydroxychloroquine (HCQ) or a small molecule inhibitor that blocks TLR3-RNA interactions strongly reduced the pro-inflammatory effects of EBER1.

Conclusion: We propose that small RNA-loaded EVs exacerbate pre-existing autoimmunity in SLE patients by engaging tubular epithelial TLR3, supporting the rationale for TLR3-blockade as therapeutic strategy in the treatment of lupus nephritis.


Disclosure: R. Baglio, None; M. Tsang-A-Sjoe, None; M. Eijndhoven, None; K. Jordanova, None; N. Groenewegen, None; J. van Weering, None; S. Verkuijlen, None; I. E. M. Bultink, None; J. Middeldorp, None; J. Roelofs, None; A. Voskuyl, None; M. Pegtel, None.

To cite this abstract in AMA style:

Baglio R, Tsang-A-Sjoe M, Eijndhoven M, Jordanova K, Groenewegen N, van Weering J, Verkuijlen S, Bultink IEM, Middeldorp J, Roelofs J, Voskuyl A, Pegtel M. Extracellular Vesicle-Mediated Delivery of EBV SMALL RNA (EBER1) Activates LUPUS Nephritis Related Antiviral Immunity in Tubular Epithelial CELLS VIA TLR3 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/extracellular-vesicle-mediated-delivery-of-ebv-small-rna-eber1-activates-lupus-nephritis-related-antiviral-immunity-in-tubular-epithelial-cells-via-tlr3/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extracellular-vesicle-mediated-delivery-of-ebv-small-rna-eber1-activates-lupus-nephritis-related-antiviral-immunity-in-tubular-epithelial-cells-via-tlr3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology